MedPath

海南涛生医药科技研究院有限公司

Ownership
-
Established
2016-10-08
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

28

NMPA:28

Drug Approvals

Telmisartan Tablets

Product Name
替米沙坦片
Approval Number
国药准字H20243836
Approval Date
May 28, 2024
NMPA

Telmisartan Tablets

Product Name
替米沙坦片
Approval Number
国药准字H20243837
Approval Date
May 28, 2024
NMPA

Memantine Hydrochloride Tablets

Product Name
盐酸美金刚片
Approval Number
国药准字H20233545
Approval Date
Jun 25, 2023
NMPA

Paracetamol and Vitamin C Effervescent Tablets

Product Name
对乙酰氨基酚维生素C泡腾片
Approval Number
国药准字H20233003
Approval Date
Jan 3, 2023
NMPA

Levofloxacin Tablets

Product Name
左氧氟沙星片
Approval Number
国药准字H20223782
Approval Date
Nov 1, 2022
NMPA

Vitamin B1 Tablets

Product Name
维生素B1片
Approval Number
国药准字H34020035
Approval Date
Jul 8, 2020
NMPA

Cefadroxil Capsules

Product Name
头孢羟氨苄胶囊
Approval Number
国药准字H34020039
Approval Date
Jun 24, 2020
NMPA

Piroxicam Tablets

Product Name
吡罗昔康片
Approval Number
国药准字H34020037
Approval Date
Jun 24, 2020
NMPA

Cefadroxil Capsules

Product Name
头孢羟氨苄胶囊
Approval Number
国药准字H34020041
Approval Date
Jun 24, 2020
NMPA

Paracetamol Tablets

Product Name
对乙酰氨基酚片
Approval Number
国药准字H34020023
Approval Date
Jun 24, 2020
NMPA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.